0       0

33rd Annual North American Cystic Fibrosis Conference


S17 - S17--CFTR: Lost in Translation: Nonsense & Rare Mutations


Nov 2, 2019 2:05pm ‐ Nov 2, 2019 3:50pm

Description

The recent success of CFTR modulators has led to a paradigm shift in the care of CF patients with many common CFTR mutations. However, for the 5-10% of patients with mutations causing premature termination codons (PTCs), or the so-called nonsense mutations, CFTR modulators alone are unable to address the fundamental defect: absence of CFTR protein production. For patients with this often severe form of CF, development of novel and innovative treatments is necessary. Furthermore, we now understand that there is heterogeneity in the molecular consequences of nonsense mutations that must inform our therapeutic approach. In this session, we will explore our current understanding and approaches to restoring function of CFTR nonsense mutations.

Learning Objectives:

  • Discuss the molecular and functional consequences of PTC mutations in CF.
  • Describe the variability of CFTR PTC mutations and how this may impact therapeutic approaches.
  • Discuss potential therapies to address CFTR PTC mutations and the challenges associated with bringing these safely to the clinic.

    Symposium Chair(s):

    Symposium Speaker(s):

    You must be logged in and own this session in order to post comments.

    Print Certificate
    Review Answers
    Print Transcript
    Completed on: token-completed_on
    Review Answers
    Please select the appropriate credit type:
    /
    test_id: 
    credits: 
    completed on: 
    rendered in: 
    * - Indicates answer is required.
    token-content
    token-speaker-name image
    token-speaker-name
    token-index
    token-content
    token-index
    token-content
    token-index
    token-content
    token-index
    token-content
    token-index
    token-content
    token-index
    token-content
    /
    /
    token-index
    token-content